Handelsavisen
prelaunch
Companies ›Healthcare ›YSPS.KL
YS
YSPS.KL — Bursa Malaysia Pharmaceuticals

Ysps.Kl

$2,09
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
5,29 %
Op margin
10,5 %
ROE
6,0 %
Net margin
6,9 %
Debt / equity
0,12
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

YSPS.KL operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Business. YSPS.KL operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,0 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning YSPS.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to YSPS.KL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    YSPS.KL operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    YSPS.KL maintains a strong liquidity position, with a current ratio of 5.27, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equivalents amount to MYR 148.1 million, which is a significant portion of its total assets of MYR 541.1 million. This liquidity is further supported by a low debt-to-equity ratio of 0.12, suggesting minimal reliance on debt financing.

    In terms of profitability, YSPS.KL reports a return on equity (ROE) of 5.99% and a return on assets (ROA) of 4.63%. These figures indicate that the company is generating a moderate return on its equity and assets, which is in line with the typical performance metrics for the pharmaceutical industry. The company's net income of MYR 25.03 million is supported by an operating income of MYR 38.24 million, reflecting efficient cost management.

    YSPS.KL's revenue is primarily concentrated in its core pharmaceutical operations, with no disclosed geographic diversification in the provided data. The company's revenue of MYR 365.12 million is derived from a single business segment, indicating a lack of diversification that could expose it to market-specific risks.

    The company's growth trajectory is supported by a positive free cash flow of MYR 17.35 million and a capital expenditure of MYR -3.47 million, indicating that it is reinvesting in its operations. However, the absence of specific growth projections or segment-level outlooks in the provided data suggests that the company's future performance may be subject to market conditions and regulatory changes.

    YSPS.KL faces low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves reduce the likelihood of financial distress. Additionally, the absence of dilution potential in the basic shares outstanding suggests that the company is not currently issuing new shares to raise capital.

    Recent events and filings for YSPS.KL do not indicate any significant changes in the company's financial or operational status. The company's financial performance and risk profile remain stable, with no major disruptions reported in the latest available data.

    Key takeaways
    • YSPS.KL maintains a strong liquidity position with a current ratio of 5.27 and significant cash reserves.
    • The company's profitability is moderate, with a return on equity of 5.99% and a return on assets of 4.63%.
    • YSPS.KL's revenue is concentrated in a single business segment, which may expose it to market-specific risks.
    • The company faces low liquidity and dilution risks, with no immediate filing-based flags detected.
    • YSPS.KL's growth is supported by a positive free cash flow and reinvestment in operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2,09
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $417.9M
    Net cashⓘ
    $97.3M
    Current ratioⓘ
    5.3
    Debt / equityⓘ
    0.1
    ROAⓘ
    4.6%
    ROEⓘ
    6.0%
    Cash conversionⓘ
    220.0%
    CapEx / revenueⓘ
    -0.9%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin10,5 %Above median
    Net Margin6,9 %Above median
    ROE6,0 %Above median
    Capex / Rev-0,9 %Above P75
    D/E0,12Above median
    Cash Conv2,20Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • YSPS.KL Market data — financials · 2026-05-30

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    YSPS.KLCanonical
    Bursa Malaysia · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage